Vontobel Holding Ltd. Sells 24,528 Shares of Hologic, Inc. $HOLX

Vontobel Holding Ltd. decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 61.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,265 shares of the medical equipment provider’s stock after selling 24,528 shares during the period. Vontobel Holding Ltd.’s holdings in Hologic were worth $1,030,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Chung Wu Investment Group LLC purchased a new stake in Hologic during the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Hologic in the 2nd quarter valued at about $33,000. Cromwell Holdings LLC grew its position in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 436 shares during the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new position in Hologic in the 2nd quarter worth approximately $40,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $74.50 on Friday. The company has a 50-day moving average price of $74.45 and a 200-day moving average price of $69.15. The stock has a market cap of $16.61 billion, a price-to-earnings ratio of 30.04, a P/E/G ratio of 2.11 and a beta of 0.70. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.34.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the prior year, the firm earned $1.01 earnings per share. Hologic’s revenue was up 6.2% on a year-over-year basis. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HOLX. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. BNP Paribas cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research report on Friday, November 21st. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Five analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus price target of $79.29.

Insider Activity at Hologic

In other news, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director owned 47,336 shares in the company, valued at $3,458,841.52. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.